Omega-3 fatty acids have long been considered one of the least controversial supplements in evidence-based health. Commonly found in fish-rich diets and widely sold as fish oil capsules, they've attracted decades of research—and mostly positive press.
Then a large study changed the conversation. That study involved over 400,000 people, and the results showed that people who took Omega-3 supplements had a 133% higher risk of developing an abnormal heart rhythm called atrial fibrillation.
If that's true, it throws a lot into question about the benefits of Omega-3 fatty acids, especially in supplement form. Before discarding fish oil, it's worth digging deeper—because there's more than meets the eye with this study, the existing trial record, and the nuances of dosing. There's an important lesson here, and this article works through it step by step.
Table of Contents
What Are Omega-3s?
Omega-3 fatty acids are a group of polyunsaturated fats that serve as an important building block for fat tissue—both in the body and in the foods people eat. Fat is one of the most efficient ways the body stores energy, and fatty acids are central to that process. Energy not used immediately can be stored as fatty acids and drawn on later.
There are three forms of Omega-3 fatty acids: alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). ALA is found in plant sources like flax seeds and soybeans, while DHA and EPA come from animal-based sources, particularly fatty fish such as salmon and mackerel.
Most over-the-counter Omega-3 supplements—such as standard fish oil capsules—contain a mixture of EPA and DHA, or EPA alone. To obtain ALA in meaningful amounts, specific plant-based Omega-3 products are required.
Omega-3s are also classified as essential nutrients, meaning the body requires them but cannot synthesise them independently. They must be obtained through food or supplementation. This essential status—combined with the high Omega-3 content of fatty fish like salmon, sardines, and mackerel—is part of why fish-rich diets attracted scientific attention as a potential driver of cardiovascular health outcomes long before supplement trials were designed.
The distinction between dietary Omega-3s from whole fish and isolated Omega-3 supplements is one that runs through the entire research story that follows—and it has meaningful implications for how the evidence should be interpreted.
What Are the Benefits of Omega-3s?
The body needs Omega-3s to function, but "proper function" is not a specific benefit in itself. The more important question is whether increasing Omega-3 intake—through diet or supplements—produces measurable health improvements.
Here is what the research suggests, and where the evidence becomes contested.
Cardiovascular Disease
One of the most commonly cited benefits of Omega-3s is heart health. Since cardiovascular disease is the leading cause of death in the United States and increasingly worldwide, any nutrient with a plausible cardiovascular effect attracts significant research attention.
Currently, the American Heart Association recommends 1–2 weekly servings of seafood to help reduce the risk of heart problems. The AHA also recommends additional EPA and DHA supplements (preferably from fish) for people already diagnosed with heart disease.
Infant Development
The evidence here is less definitive. Some recommendations suggest that additional Omega-3s during pregnancy and breastfeeding can benefit infant development.
However, it is not yet clear whether supplements produce the same effect as fish, and fish choices must be carefully managed to avoid mercury contamination—a particular concern during pregnancy and for infants. Many commercial infant formulas already contain added DHA.
Cancer Prevention
As the second leading cause of death for Americans, cancer prevention is a priority across nutritional research. Some studies have suggested that people with diets higher in Omega-3s have a lower risk of breast cancer and possibly colorectal cancer. The evidence is not conclusive, however, and a large clinical trial—the VITAL trial—found no supporting evidence of cancer risk reduction from Omega-3 supplementation.
Other Conditions
Scattered studies—mostly small in scope—have indicated potential benefits of Omega-3s for several other conditions, including dementia and Alzheimer's disease, rheumatoid arthritis, ADHD, childhood allergies, and cystic fibrosis. The evidence for these applications is thin and requires significantly more research before health authorities would consider recommending Omega-3s for them.
A common thread through this section: some studies suggest a benefit, while others find no supporting evidence. Understanding why requires a closer look at the methodology and quality of the underlying trials.
The Source and Existing Body of Evidence
The most widely-cited benefit of Omega-3s is their positive effect on heart health. One of the primary sources for this claim is a study from 2006. That study surveyed people who commonly ate fish and found that among those with diets higher in Omega-3-rich fish, there was a 36% lower risk of dying from heart disease. The data showed a fairly strong correlation: the more Omega-3s consumed from fish, the lower the risk of heart disease death.
The methodological gap is important to recognise. Surveys show an association between fish-rich diets and better cardiovascular outcomes. An ingredient in fish—Omega-3s—is identified as the probable active agent. Supplements are then created and marketed as delivering those same benefits. But does the supplement replicate the dietary effect? This is where the scientific controversy begins.
In 2007, an open-label study called the JELIS study enrolled over 18,000 people with high cholesterol levels. The cohort was followed for an average of 4.6 years, with some patients assigned an EPA Omega-3 supplement and others receiving no supplement.
The results were moderately promising: the group that took EPA supplements had a 19% lower risk of heart disease. However, the study was open-label—patients knew whether they were receiving the supplement—which introduces a significant confounding factor. The gold standard for clinical evidence is the double-blind, placebo-controlled trial.
The needed double-blind trial arrived in 2019 in the form of the REDUCE-IT trial. This trial enrolled over 8,100 patients and compared high-dose EPA (icosapent ethyl, marketed as Vascepa) at 4g per day versus a mineral oil placebo. It showed a 25% reduction in major cardiovascular events in the EPA group—a striking result.
However, the placebo choice drew substantial criticism. Mineral oil can be toxic and was found to raise inflammation and LDL cholesterol in the control group. As a result, it is unclear whether the EPA group genuinely benefited, or whether the mineral oil worsened outcomes in the placebo group, artificially inflating the apparent benefit. This controversy is significant enough that entire papers have been written addressing it, including 2022's "When Is a Placebo Not a Placebo." The choice of placebo matters enormously in trial design.
Further confounding evidence comes from the STRENGTH trial, a randomised double-blind clinical trial comparing EPA and DHA versus corn oil in approximately 13,000 high-cardiovascular-risk patients, run from 2014 to 2020. The trial was halted early after interim analysis showed no meaningful difference between groups on major adverse cardiovascular events. Notably, the Omega-3 group in STRENGTH also showed a higher rate of atrial fibrillation compared to the corn oil group—a signal that would become more relevant with later research.
The largest cardiovascular Omega-3 trial to date is the VITAL trial, which enrolled over 25,000 people receiving Omega-3 at approximately 840 mg per day. VITAL found a 28% reduction in the risk of heart attack in the Omega-3 group—a meaningful positive finding at a much lower dose than STRENGTH or REDUCE-IT.
Further supporting cardiovascular benefit, a large Mayo Clinic meta-analysis synthesised over 40 studies with a combined total of 135,000 patients. Its conclusion: supplementation with EPA and DHA "is an effective lifestyle strategy for CVD prevention, and the protective effect probably increases with dosage."
The New Study on Omega-3s
Despite the mixed picture from clinical trials, observational research has continued to accumulate. The study that sparked the most recent debate is a large UK Biobank analysis that examined long-term supplement use and cardiovascular outcomes in a way no previous clinical trial had been powered to detect.
The UK Biobank observational study—enrolling participants from 2006 to 2010 with follow-up continuing through 2021—represents the largest population-level dataset yet applied to this question, with over 415,000 participants.
The headline finding is striking: people who regularly used Omega-3 supplements had a 133% higher risk of developing atrial fibrillation compared to non-users. Atrial fibrillation is a condition in which the heart cannot pump blood as effectively as it should, and it substantially increases the risk of stroke.
At the same time, the study found that among people who already had diagnosed atrial fibrillation, those taking Omega-3 supplements had a lower risk of major cardiovascular events and cardiovascular death compared to those who did not supplement.
Overall, the study's conclusion was that "Regular use of fish oil supplements might be a risk factor for atrial fibrillation and stroke among the general population but could be beneficial for progression of cardiovascular disease from atrial fibrillation to major adverse cardiovascular events, and from atrial fibrillation to death." In other words, Omega-3 supplementation appears to help slow disease progression in people who already have atrial fibrillation, while potentially increasing the risk of developing it in the general population.
This finding is not entirely without precedent. The STRENGTH trial also observed a higher rate of atrial fibrillation in its Omega-3 group. The VITAL trial did not—and an important variable between the two is dosage. STRENGTH used 4g per day; VITAL used approximately 840 mg per day. The UK Biobank study does not specify dose, since it relied on self-reported supplement use, which is a meaningful limitation of observational research.
Lessons and Takeaways
The existing evidence points to two important principles.
One: Omega-3 effects are not uniform across populations. If Omega-3 supplementation appears to benefit people who already have atrial fibrillation while potentially increasing the risk of developing it in those without the condition, a blanket "take Omega-3s for heart health" recommendation becomes more complicated. Subgroup matters. An individual's cardiovascular history and risk profile should inform whether supplementation makes sense.
Two: Dose matters considerably. The atrial fibrillation signal appears most clearly at higher doses—4g per day in STRENGTH, and unspecified (but likely variable) doses in the UK Biobank observational data. The VITAL trial at approximately 840 mg per day did not observe an atrial fibrillation risk increase, and still found a 28% reduction in heart attack risk. The evidence does not support the assumption that more is always better with Omega-3 supplementation.
This is worth emphasising because "megadosing"—taking very high amounts of a supplement in the hope of amplifying its benefits—is a common pattern that can backfire. Higher doses of Omega-3s may provide marginal additional cardiovascular benefit while introducing a meaningful atrial fibrillation risk that is not present at lower doses. The dose-response relationship here is not linear, and the evidence profile looks meaningfully different at 1g versus 4g per day.
It's also worth noting that the UK Biobank study is observational, not a randomised controlled trial. Observational data cannot establish causation—people who choose to take Omega-3 supplements may differ from those who don't in ways that confound the results (diet quality, underlying health conditions, access to healthcare, and so on). This does not make the finding irrelevant, but it does mean it should be interpreted alongside—not instead of—the randomised trial evidence.
The current body of evidence suggests that Omega-3 supplementation at approximately 1g per day—roughly in line with VITAL trial dosing—provides a meaningful cardiovascular benefit without the atrial fibrillation signal seen at higher doses. Anyone considering Omega-3 supplementation, particularly at higher doses, should discuss their cardiovascular history and risk profile with a healthcare professional before starting.
Sources
- Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study: https://bmjmedicine.bmj.com/content/3/1/e000451
- Omega-3 Fatty Acids Consumer Factsheet: https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer/
- Fish Intake, Contaminants, and Human Health – Evaluating the Risks and the Benefits: https://jamanetwork.com/journals/jama/fullarticle/203640
- Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis: https://pubmed.ncbi.nlm.nih.gov/17398308/
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia: https://pubmed.ncbi.nlm.nih.gov/30415628/
- When Is a Placebo Not a Placebo: https://jamanetwork.com/journals/jamacardiology/article-abstract/2797283
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial: https://pubmed.ncbi.nlm.nih.gov/33190147/
- Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer: https://www.nejm.org/doi/10.1056/NEJMoa1811403
- Effect of Omega-3 Dosage on Cardiovascular Outcomes – An Updated Meta-Analysis and Meta-Regression of Interventional Trials: https://www.mayoclinicproceedings.org/article/S0025-6196(20)30985-X/fulltext
